Exclusive: Myeloid Therapeutics raises $73M, bringing in ARCH ahead of in vivo program entering the clinic

Myeloid Therapeutics has raised a $73 million Series A2 round that brings ARCH Venture Partners in as a new investor, as the biotech prepares to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex­clu­sive: Myeloid Ther­a­peu­tics rais­es $73M, bring­ing in ARCH ahead of in vi­vo pro­gram en­ter­ing the clin­ic